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and common comorbid conditions included diabetes (27.3%), tumor (23.6%) and 
moderate or severe renal disease (21.2%). Simvastatin (7.3%), lisinopril (5.9%) and 
hydrocodone bitartrate/acetaminophen (5.1%) were the most frequently prescribed 
medications. During the follow-up period, PC patients had evidence of the follow-
ing health care utilizations: Medicare carrier (98.0%), Durable Medical Equipment 
(DME, 32.1%), Home Health Agency (HHA, 12.1%), outpatient visits (75.9%) and inpa-
tient hospital (29.5%), Skilled Nursing Facility (SNF, 7.2%) and hospice admissions 
(5.4%) and prescription drug (part D event) claims (43.7%). PC patients incurred 
higher Medicare carrier ($6,330), DME ($328), HHA ($647), outpatient ($19,041), 
inpatient ($5,814), SNF ($1,229), hospice ($475), pharmacy ($1,144) and total costs 
($35,008). ConClusions: Patients who were enrolled in Medicare and diagnosed 
with PC had high utilization of Carrier and outpatient services, as well as frequent 
comorbid conditions, resulting in considerable health care expenditures.
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objeCtives: In previous studies in chronic lymphocytic leukemia (CLL), adverse 
events (AEs) associated with commonly used therapies have primarily consisted 
of infusion reaction, myelotoxicity, and infection. This study estimated the cost of 
specific AEs per course of therapy associated with commonly used first-line treat-
ment regimens for CLL in the United States. Methods: This retrospective claims 
data analysis used Truven Health Analytics MarketScan® commercial and supple-
mental Medicare databases from January 2005 through August 2012. Eligible patients 
were ≥ 18 years, had a diagnosis of CLL, and continuous enrollment for ≥ 6 months 
prior to diagnosis. All patients received ≥ 1 dose of one of the following 5 regimens: 
fludarabine, cyclophosphamide, and rituximab (FCR); bendamustine plus rituximab 
(BR); chlorambucil, fludarabine plus rituximab (FR); or rituximab. AEs were identified 
from ICD-9-CM codes that either explicitly described the event of interest or that 
described interventions that were specific to the AE. Costs related to each AE were 
summed from diagnosis to the end of initial therapy. Drug costs of CLL therapies 
were excluded. Adjusted costs were estimated using a propensity-weighted general-
ized linear model (GLM), which controlled for differences in baseline characteristics 
across treatment groups. Results: Of 2,035 patients, 497 received FCR, 130 received 
BR, 449 received chlorambucil, 297 received FR, and 662 received rituximab. Mean 
age was 69.5 years (SD: 12.4) and 64% were male. Comorbidities included diabetes 
(19%), COPD (16%), and cardiovascular (14%) disease. AE results (frequency; adjusted 
cost; and 95% CI, respectively) were as follows: infusion reaction (40%; $4482; $4141-
$4862), anemia (35%; $8894; $8267-$9586), infection (26%; $7163; $6648-$7733), dysp-
nea (9%; $859; $751-$989), neutropenia (8%; $5406; $4629-$6367), febrile neutropenia 
(5%; $17,274; $14,374-$21,010), thrombocytopenia (2%; $12,621; $8933-$18,651), and 
leukopenia (1%; $1720; $1218-$2539). ConClusions: Infusion reaction, myelotoxic-
ity, and infection have substantial economic costs in CLL, which may be reduced by 
improved patient management.
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objeCtives: To collect health care resource utilization (HCRU) in the manage-
ment of chronic lymphocytic leukemia (CLL) patients who have relapsed/refrac-
tory disease, and had at least one previous chemotherapy treatment. Methods: 
A retrospective, longitudinal, cohort study design is being used involving three 
cancer centres in Ontario, Canada. A convenience sample of 90 CLL patients was 
selected with inclusion criteria of adult age at diagnosis, date of diagnosis between 
January 1, 2006 to 2012, relapsed/refractory disease that required at least one previ-
ous therapy, and minimum of one oncology visit. Demographics and HCRU data were 
collected with descriptive statistics to be presented. Costs are in 2013 Canadian dol-
lars. Results: At the Juravinski Cancer Centre (Hamilton, Ontario), 30 CLL patients 
met the study inclusion criteria. 22 were male with the mean age at diagnosis being 
65.2 years (range 41-86 years). 43% (13/30) of the interim cohort had genetic test-
ing. 73.3% of patients (22/30) received fludarabine-based chemotherapy as first-line 
treatment. 13.6% (3/22) were re-treated with fludarabine as second-line treatment. 
26.7% of patients (8/30) received chlorambucil as first-line treatment. Of those, 2 
patients were re-treated with chlorambucil as second-line treatment, 4 received 
fludarabine-based chemotherapy, and 2 did not receive further treatment. 40% of 
patients (12/30) were given rituximab. 90% of patients who needed other medica-
tions utilized a mean number of 6.0 (0-15) drugs. Half of the cohort visited the emer-
gency department a total of 19 times and experienced 25 adverse events. The total 
cost of diagnostic tests/procedures was $17,502, $28,895 for hospitalizations, and 
$49,794 for specialist visits. ConClusions: Preliminary results from one cancer 
centre indicate substantial HCRU associated with CLL management. The authors 
plan to complete data extraction at the two remaining cancer centres in order to 
determine HCRU and cost results for the full cohort.
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years, 51% female, 97% commercially-insured). Unadjusted 1-year post-failure costs 
increased by LOT for total health care (1L:$78,667, 2L:$99,624, 3L:$181,029) and medi-
cal services (i.e., non-pharmacy) (1L:$35,578, 2L:$51,078, 3L:$146,768), as did medical 
costs as a proportion of total costs (1L:45%, 2L:51%, 3L:81%). In adjusted analyses, 
compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 
on RR 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% 
CI 1.16-2.64), 38% higher total costs (95% CI 1.14-1.68), and 73% higher medical costs 
(95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L 
vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly. ConClusions: 
The burden of TKI treatment failure increases by LOT, due to increased MRU and 
associated costs. More efficacious treatment used in early therapy lines may reduce 
downstream costs by preventing treatment failure.
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objeCtives: In recent years, breast cancer remains the leading cause of death 
in women worldwide. Evaluating the economic burden of breast cancer is very 
important due to long-term treatment with expensive drugs and medical services. 
In Vietnam related studies has not been conducted until now. This is also the aim of 
this study. Methods: The cost of breast cancer has been evaluated using pharma-
coeconomic method “cost of illness” by following formula: COI = DC + IC in which: 
COI - cost of illness, DC- direct cost, IC- indirect cost A tree-decision model has been 
developed to evaluate the cost of different stages of breast cancer. This analysis was 
conducted based on the perspective of health insurance companies, therefore only 
direct medical costs were evaluated. The price of drugs and medical services have 
been averaged from the price-list of some major hospitals in Vietnam. The cost of 
disease for the whole society of Vietnam has been evaluated based on epidemiologi-
cal data in Vietnam in 2013. Results: The average cost of treatment per year of 
breast cancer in stage 0- I, II, III, IV accounts for 33,166,886; 287,057,068; 325,116,474 
and 153,352,776 VND, respectively. In the structure of average cost with the increas-
ing in severity of disease, the percentage of drug costs increase (from 28.7% in stage 
0-I to 95.1% in stage 4) and the percentage of medical services decrease (from 71.3% 
in stage 0-I to 4.9% in stage 4). The cost of breast cancer for the whole society of 
Vietnam resulted in around 6,633 billion VND. ConClusions: The cost of breast 
cancer increases following the severity level of disease with the increasing percent-
age of drugs costs and reducing percentage medical services costs. The high cost of 
breast cancer for the whole society of Vietnam needs to be concerned to conduct 
the relevant health care policies.
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objeCtives: Evaluate the economic burden of non-small cell lung cancer (NSCLC) 
in Vietnam. Methods: Economic burden analysis has been conducted, following 
which the economic burden of NSCLC for the whole society of Vietnam has been 
evaluated by following formulas: C = ∑Pi x COIi in which, C: economic burden of 
NSCLC in Vietnam; Pi: number of patients in stage i of NSCLC in Vietnam, COIi: cost 
of NSCLC in stage i The analysis has been conducted based on the perspective of 
health insurance companies, therefore only medical direct cost has been evaluated. 
The cost of drugs and medical services has been averaged from the relevant drugs 
and medical services of some major hospitals in Vietnam. The number of patients in 
every stage of NSCLC has been retrieved from epidemiological database of Vietnam in 
2010. The model has been developed to evaluate the economic burden of NSCLC and 
also further adapt the changes of price and epidemiological data over years. Results: 
The economic burden of NSCLC for the whole society of Vietnam is over 3,517 billion 
VND. In the structure of economic burden of NSCLC, the economic burden for drugs 
consists of 73.9% (2,600 billion VND), which is around 3 times higher than economic 
burden for medical services (900 billion VND). Comparing the economic burden of 
NSCLC by stages, it has been found that the economic burden of NSCLC increases 
with the increasing in the severity of disease. However stage III with the less severity 
than stage IV has the highest economic burden with the amount of 2,490 billion VND 
due to the high cost of treatment and high number of patients. ConClusions: The 
high economic burden of NCSLC should be considered to conduct the relevant health 
care policies, especially with high-cost drugs and patients in late stages of disease.
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objeCtives: To examine the economic burden and health care utilizations of U.S. 
Medicare patients diagnosed with prostate cancer (PC). Methods: A retrospec-
tive analysis was conducted using national Medicare claims data (01JAN2008-
31DEC2010). Medicare beneficiaries diagnosed with PC were identified using 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis code 185.xx, and the initial diagnosis date designated as the index date. 
Eligible patients were required to have 1 year continuous enrollment pre- and post-
index date. Charlson Comorbidity Index (CCI) score and baseline comorbid condi-
tions were examined for the baseline period. Prescribed medications were captured 
within 60 days post-index date. Health care utilization and costs were measured 
for the follow-up period, and costs were adjusted to 2010 U.S. dollars. Results: 
A total of 21,616 PC patients were identified, of which 99.2% were male and 84.4% 
Caucasian. PC patients enrolled in Medicare had a mean age at 76.1 years and more 
often resided in the Southern U.S. region (37.7%). The baseline CCI score was 1.76, 
